News Tech: Bharat Biotech on Wednesday said its rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunise children from life-threatening diarrhoeal disease.
Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria.
Nigeria currently accounts for 14 per cent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world.
”We are committed to supporting and reducing the infectious disease burden amongst children in the developing world, and to ensure nations like Nigeria in the African continent have access to cost-effective world-class interventions for infants and vulnerable populations,” Bharat Biotech chairman and managing director Krishna Ella said in a statement.
Rotavirus is one of the leading causes of diarrheal disease in the world and is responsible for over 40 per cent of diarrhoea in children.
It accounts for about 2.15 lakh of the 5.25 lakh under-five mortality worldwide each year, which are attributed to diarrheal diseases, making it the most common cause of severe diarrhoea. Rotavac received WHO-prequalification in January 2018.
The company said it has developed the vaccine under a public-private partnership with the Department of Biotechnology and 16 international partners, making it the largest ever social innovation project for public health. Bharat Biotech is a global leader in rotavirus vaccines, with one of the largest manufacturing capacities.
(This story has not been edited by Our Editor Team and is generated from a Feed.)